Navigation Links
GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
Date:8/14/2012

WASHINGTON, D.C. The George Washington University School of Public Health and Health Services (GW) today released a report representing consensus findings from a cross-section of stakeholders that could help transform the process used to evaluate interventions to treat obesity, a public health crisis that now affects one in three adults. The report, "Obesity Drug Outcome Measures," results from a stakeholder dialogue group convened by GW that, over a period of nine months, explored why development and approval of obesity drugs have proven so difficult.

"At a time when so many Americans suffer with obesity and are faced with limited treatment options, there has been a rising call to review the emerging science on obesity to update the framework used when evaluating obesity drugs," said Christine Ferguson, J.D., Professor in the Department of Health Policy. "The FDA, under a reauthorized Prescription Drug User Fee Act, is likely to take a wider, more comprehensive look at how drugs developed to treat obesity affect how individuals with obesity feel and function. This report may help update the risk-benefit framework."

Participants in the stakeholder group all contributed to the consensus report findings and included consumer advocates, obesity experts, researchers and clinicians. Officials from the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) participated in the dialogue process, but were not asked to endorse the final report.

The consensus report outlines a series of new approaches that should be considered by the FDA when evaluating the benefits and risks of obesity drugs including:

  • Obesity affects everyone differently. Evaluating the benefits and risks of interventions should reflect the various considerations within the different categories of obesity based on feeling, functioning and health impairments.
  • Obesity drugs may provide an additional option for helping individuals who do not respond, or inadequately respond, to other interventions.
  • Potential pharmaceutical interventions should be reviewed as obesity treatments rather than weight loss agents and should be limited to only those for whom they are medically appropriate.
  • The benefit-risk evaluation of treatment with obesity drugs should extend beyond numerical weight loss to improvement in feeling and functioning.


'/>"/>
Contact: Melissa Warren
mwarren@ccapr.com
202-609-6010
Chandler Chicco Agency
Source:Eurekalert

Related medicine news :

1. Adolescents in substance abuse programs report using others med marijuana
2. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
3. Survival rates for premature babies in high-level NICUs are better than previously reported
4. New report describes 7 essential steps toward an AIDS-free generation
5. Cost Keeps Many Americans From Good Dental Care: Report
6. Inactivity May Kill as Many Worldwide as Smoking: Report
7. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
8. Reducing Ozone Limits Would Save Lives, Report States
9. Reporting of hospital infection rates and burden of C. difficile
10. Report focuses on sustainability of infectious disease surveillance
11. 20% of U.S. Women Uninsured in 2010, Up From 15% in 2000: Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization ... affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for ... July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition of ... in Biology from LSU, graduating summa cum laude. He attended Emory University School of ... in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to ... – of - living - adjustment (COLA) is a bad deal for older and ... consumer price index (CPI) would grow even more slowly than the conventional one that ...
(Date:7/20/2017)... ... 19, 2017 , ... Med Tech Solutions (MTS), a leading health care cloud ... of Constellation Inc., a move that will help the company better serve its clients ... the acquisition is expected to help MTS expand its presence in the ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: